Bel Air Investment Advisors’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Bel Air Investment Advisors’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	$721K	Buy	+54,053	New	+$855K	0.1%	67

Other funds holding ECYT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AWMDMG

Austin W. Marxe & David M. Greenhouse New York $733M AUM 21.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RIM

RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bel Air Investment Advisors's ECYT Position: Q3 2013 in Review

Bel Air Investment Advisors opened a new position in Endocyte, Inc. Common Stock (ECYT) in Q3 2013: 54,053 shares worth $721K. The stake represents 0.1% of the portfolio and ranks #67 among its holdings.

101 funds tracked by Wall St. Rank hold ECYT as of Q3 2013.

Bel Air Investment Advisors held 54,053 shares of Endocyte, Inc. Common Stock worth $721K as of Q3 2013.
Endocyte, Inc. Common Stock was a new Bel Air Investment Advisors position in Q3 2013.
Endocyte, Inc. Common Stock made up 0.1% of Bel Air Investment Advisors's portfolio in Q3 2013, its #67 holding.
101 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q3 2013.

Based on Bel Air Investment Advisors's 13F filing for Q3 2013, filed 12 Nov 2013.